Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Marginal zone lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    112 result(s) found for: Marginal zone lymphoma. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2017-003149-56 Sponsor Protocol Number: OLYMP-1 Start Date*: 2018-05-14
    Sponsor Name:University Hospital Ulm
    Full Title: OBINUTUZUMAB in MARGINAL ZONE LYMPHOMA
    Medical condition: Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062113 Splenic marginal zone lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000693-45 Sponsor Protocol Number: RCOMP05 Start Date*: 2005-02-24
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and Rituximab
    Medical condition: Treatment of patients with newly diagnosed splenic marginal non Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062113 Splenic marginal zone lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003150-16 Sponsor Protocol Number: COUP-1 Start Date*: 2018-11-21
    Sponsor Name:University Hospital Ulm
    Full Title: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
    Medical condition: Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062113 Splenic marginal zone lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004916-23 Sponsor Protocol Number: MORE Start Date*: 2014-04-28
    Sponsor Name:Ospedale San Raffaele
    Full Title: Monotherapy with Ofatumumab for RElapsed/refractory Splenic B-cell marginal zone lymphoma (MORE)
    Medical condition: Splenic B-cell marginal zone lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062113 Splenic marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004808-37 Sponsor Protocol Number: HD-K Start Date*: 2011-12-06
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Phase II clinical study on the activity of salvage therapy with high doses of oral clarithromycin in patients with extranodal marginal zone relapsed or refractory lymphoma
    Medical condition: patients with extranodal marginal zone relapsed or refractory lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015823 Extranodal marginal zone B-cell lymphoma (MALT type) recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015824 Extranodal marginal zone B-cell lymphoma (MALT type) refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011725-14 Sponsor Protocol Number: IELSG 34 Start Date*: 2010-06-23
    Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)
    Full Title: IELSG 34: A Multicenter Phase II study to evaluate the clinical activity and the safety profile of everolimus (RAD001) in marginal zone B-cell lymphomas (MZL) EudraCT Number 2009-011725-14
    Medical condition: Relapsed or refractory marginal zone B-cell lymphomas.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029463 LLT
    9.1 10041652 LLT
    9.1 10015823 LLT
    9.1 10015824 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001768-31 Sponsor Protocol Number: ZENO-01 Start Date*: 2012-09-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma)
    Medical condition: MALT Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004289-42 Sponsor Protocol Number: ZENO-06021957 Start Date*: 2008-03-20
    Sponsor Name:National and Kapodistrian University of Athens
    Full Title: 90Y ibritumomab tiuxetan (Zevalin®) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma)
    Medical condition: extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001245-14 Sponsor Protocol Number: CC-5013-NHL-007 Start Date*: 2013-12-13
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lym...
    Medical condition: Relapsed/refractory indolent lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060707 MALT lymphoma LLT
    20.0 100000004851 10041650 Splenic marginal zone lymphomas HLT
    20.0 100000004851 10029461 Nodal marginal zone B-cell lymphomas HLT
    20.0 100000004851 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) IT (Completed) PT (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003495-36 Sponsor Protocol Number: S10BEOF01 Start Date*: 2012-05-08
    Sponsor Name:SENDO TECH
    Full Title: A multicenter pilot phase II study for the preliminary evaluation of feasibility, activity and safety of the administration of Bendamustine and Ofatumumab in combination in marginal zone B-cell lym...
    Medical condition: marginal zone B-cell lymphomas (MZL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029463 Nodal marginal zone B-cell lymphoma recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029464 Nodal marginal zone B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000767-41 Sponsor Protocol Number: AGMT_MALT Start Date*: 2008-04-30
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Phase II Trial of Rituximab Plus 2CdA in Patients with Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
    Medical condition: Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001284-24 Sponsor Protocol Number: BGB-3111-214 Start Date*: 2019-04-01
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma
    Medical condition: Relapsed or Refractory Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000880-28 Sponsor Protocol Number: IELSG36 Start Date*: 2012-10-25
    Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)
    Full Title: Bendamustine and Rituximab for the treatment of Splenic Marginal Zone Lymphoma. The IELSG-36 phase II prospective study.
    Medical condition: Splenic Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062113 Splenic marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004896-38 Sponsor Protocol Number: IELSG38 Start Date*: 2014-02-13
    Sponsor Name:IELSG (International Extranodal Lymphoma Study Group)
    Full Title: A PHASE II STUDY OF CHLORAMBUCIL IN COMBINATION WITH SUBCUTANEOUS RITUXIMAB FOLLOWED BY MAINTENANCE THERAPY WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF ...
    Medical condition: Patients with MALT Lymphoma treated with chlorambucil and rituximab followed by maintenance treatment with subcutaneous rituximab
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004396-38 Sponsor Protocol Number: IELSG49 Start Date*: 2021-06-07
    Sponsor Name:IELSG - International Extranodal Lymphoma Study Group
    Full Title: Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL)
    Medical condition: Marginal Zone Lymphomas refractory to or in first or greater relapse after prior systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004596-11 Sponsor Protocol Number: IELSG 25B Start Date*: 2005-08-01
    Sponsor Name:International Extranodal Lymphoma Study Group
    Full Title: Phase II Study of VELCADETM in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with more than one prior systemic therapy regimen (X05142)
    Medical condition: lymphoma of MALT
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004594-29 Sponsor Protocol Number: IELSG 25A Start Date*: 2005-08-01
    Sponsor Name:International Extranodal Lymphoma Study Group
    Full Title: Phase II Study of VELCADETM in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regimen (X05142)
    Medical condition: lymphoma of MALT
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004081-18 Sponsor Protocol Number: JCAR017-FOL-001 Start Date*: 2020-08-04
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (...
    Medical condition: Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10016895 Follicle centre lymphomas diffuse predominantly small cell HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029460 Nodal marginal zone B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007725-39 Sponsor Protocol Number: MALT2008-01 Start Date*: 2009-05-05
    Sponsor Name:Fundación GEL/TAMO
    Full Title: ESTUDIO MULTICENTRICO FASE II, NO ALEATORIZADO, DE RITUXIMAB EN COMBINACIÓN CON BENDAMUSTINA COMO PRIMER TRATAMIENTO SISTÉMICO EN LINFOMA DE CÉLULAS B DE LA ZONA MARGINAL EXTRAGANGLIONAR DEL TEJID...
    Medical condition: Linfoma no hodgkiniano marginal de tipo MALT en una primera línea de inmunoquimioterapia.
    Disease: Version SOC Term Classification Code Term Level
    9 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000970-12 Sponsor Protocol Number: INCB50465-204 Start Date*: 2017-10-13
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor.
    Medical condition: Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) BE (Completed) DK (Completed) FR (Ongoing) PL (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 18:43:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA